YS Biopharma (YS) Set to Announce Quarterly Earnings on Friday

YS Biopharma (NASDAQ:YS) will be posting its quarterly earnings results before the market opens on Friday, April 19th.

YS Biopharma (NASDAQ:YS) last posted its earnings results on Monday, January 22nd. The company reported ($0.16) EPS for the quarter. The company had revenue of $13.64 million during the quarter. On average, analysts expect YS Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

YS Biopharma Price Performance

YS Biopharma stock traded up $0.08 during midday trading on Wednesday, hitting $0.94. 413,726 shares of the company were exchanged, compared to its average volume of 199,102. YS Biopharma has a fifty-two week low of $0.35 and a fifty-two week high of $2.37. The business has a fifty day simple moving average of $0.61 and a two-hundred day simple moving average of $0.57. The company has a quick ratio of 1.09, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Hedge Funds Weigh In On YS Biopharma

A number of hedge funds have recently bought and sold shares of YS. FMR LLC purchased a new position in YS Biopharma during the first quarter worth approximately $1,864,000. Barclays PLC purchased a new position in YS Biopharma during the second quarter worth approximately $150,000. Finally, XTX Topco Ltd purchased a new position in YS Biopharma during the second quarter worth approximately $31,000. Hedge funds and other institutional investors own 52.64% of the company’s stock.

YS Biopharma Company Profile

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.